<DOC>
	<DOCNO>NCT03015181</DOCNO>
	<brief_summary>This first study VRC-HIVMAB075-00-AB ( VRC07-523LS ) monoclonal antibody ( MAb ) healthy adult . It phase 1 , dose-escalation study examine safety , tolerability , dose , pharmacokinetics VRC07-523LS . The hypothesis VRC07-523LS safe administration healthy adult intravenous ( IV ) subcutaneous ( SC ) rout . Healthy adult 18-50 year age enrol . There 4 open-label , dose escalation VRC07- 523LS 1 mg/kg IV 40 mg/kg IV , 1 route escalation IV SC , 2 open-label group assess repeat dose . Groups 1-5 expect include 3 subject Groups 6-7 expect enroll 5 sjubjects . Subjects follow 24 week last study product administration .</brief_summary>
	<brief_title>VRC 605 : A Phase 1 Dose-Escalation Study Safety Pharmacokinetics Human Monoclonal Antibody , VRC-HIVMAB075-00-AB ( VRC07-523LS ) , Administered Intravenously Subcutaneously Healthy Adults</brief_title>
	<detailed_description>This first study VRC-HIVMAB075-00-AB ( VRC07-523LS ) monoclonal antibody ( MAb ) healthy adult . It phase 1 , dose-escalation study examine safety , tolerability , dose , pharmacokinetics VRC07-523LS . The hypothesis VRC07-523LS safe administration healthy adult intravenous ( IV ) subcutaneous ( SC ) rout . Healthy adult 18-50 year age enrol . There 4 open-label , dose escalation VRC07- 523LS 1 mg/kg IV 40 mg/kg IV , 1 route escalation IV SC , 2 open-label group assess repeat dose . Groups 1-5 expect include 3 subject Groups 6-7 expect enroll 5 sjubjects . Subjects follow 24 week last study product administration .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>INCLUSION CRITERIA : A volunteer must meet following criterion : Able willing complete inform consent process . 18 50 year age . Based history examination , must good general health without history condition list exclusion criterion . Willing blood sample collect , store indefinitely , use research purpose . Able provide proof identity satisfaction study clinician complete enrollment process . Willing adhere reduce risk sexual behavior study participation . Screening laboratory value within 84 day prior enrollment must meet following criterion : WBC 2,50012,000/mm^3 . WBC differential either within institutional normal range accompany PI designee approval . Platelets = 125,000 400,000/mm^3 . Hemoglobin within institutional normal range . Creatinine le equal 1.1 x ULN . ALT le equal 1.25 x ULN . Negative HIV infection FDA approve method detection . FemaleSpecific Criteria : If woman reproductive potential sexually active male partner , agree use effective mean birth control time study enrollment last study visit , monogamous partner vasectomy . Negative BetaHCG ( human chorionic gonadotropin ) pregnancy test ( urine serum ) day enrollment woman presume reproductive potential . EXCLUSION CRITERIA : A volunteer exclude one follow condition apply : Previous receipt license investigational monoclonal antibody . Weight &gt; 115 kg . Any history severe allergic reaction generalize urticaria , angioedema anaphylaxis prior enrollment reasonable risk recurrence study . Hypertension well control . Woman breastfeed , plan become pregnant study participation . Receipt investigational study agent within 28 day prior enrollment . Any chronic clinically significant medical condition opinion investigator would jeopardize safety right volunteer , include limited : diabetes mellitus type I , chronic hepatitis ; OR clinically significant form : drug alcohol abuse , asthma , autoimmune disease , psychiatric disorder , heart disease , cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 16, 2017</verification_date>
	<keyword>Broadly Neutralizing</keyword>
	<keyword>HIV Prevention</keyword>
	<keyword>Anti-Drug Antibody</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Immune Response</keyword>
</DOC>